Logo Join | About | Forum| Help | Bookmark | Login
Home Stories Groups People Marketplace | FREE Benefits
Newron Pharmaceuticals SpA, a research and development company focused on novel CNS and pain therapies, has announced that the topline top-line results of its Serena study, a phase-IIb/III study of ralfinamide in patients with at least moderate Neuropathic Low Back Pain (NLBP) failed to show any significant difference between ralfinamide and placebo.
 
 
Tags: back-pain, lower-back-pain, upper-low-back-pain-relief, chronic-back-pain
Posted By: Back Pain Posted Today
All Votes: 1
Bookmark
Comments (0) | Who voted on this story (1) | Email this story
 

UnitedProject.org Inc. (c) 2006-2010 All content published on UnitedProject.org is provided for informational purposes only and is not meant to substitute for the advice, diagnosis or treatment provided by your physician or other healthcare professionals. If you think you are experiencing a medical problem or an emergency please contact your physician, local emergency room or call 911. Healthcare benefits and discounts are not insurance and not intended as a substitute for health insurance. Except when other source is cited, all content posted by members is licensed under Creative Commons Public Domain License.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.


Site last updated 02/10/12 - loaded in 0.0706 seconds
Website and Case Management Software powered by Paas Cloud Computing Platform